retatrutide obesity clinical trial results New Phase 3 data just dropped 👀 Eli Lilly's reported average weight loss approaching 30%, with some patients achieving historically associated with bariatric surgery. A few important caveats The numbers from Lilly's Phase

With the ever-increasing number of patients being prescribed GLP-1 RAs, more research needs to be conducted to investigate their potential impact in other areas of healthcare

Survodutide vs Retatrutide: Dual vs Triple Agonist Survodutide and retatrutide are both investigational obesity drugs that add glucagon to GLP-1, but retatrutide goes a step further by also targeting GIP

Characterized by intermittent hypoxia (IH), OSA is associated with increased ROS and RNS, adversely impacting cardio-/cerebro-vascular conditions in OSA patients

This can lead to mild nutritional ketosis, a metabolic state in which the body burns fat for fuel

Join my newsletter here for a FREE neurodiversity report writing guide